Abstracts Archive - Page 737 of 2607 - ACR Meeting Abstracts

Abstract Number: 0478 • ACR Convergence 2021
Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method
Marie Binvignat¹, Gabriel Pires¹, Nicolas Tchitchek¹, Alice Courties², Felicie Costantino³, David Klatzmann¹, Bernard Combe⁴, Maxime Dougados⁵, Pascal Richette⁶, Encarnita Mariotti-Ferrandiz¹, Francis Berenbaum⁷ and Jeremie Sellam⁸, ¹Sorbonne Universite, Paris, France, ²Service de Rhumatologie, AP-HP Hopital Saint-Antoine, Sorbonne Universite, INSERM, Centre de Recherche Saint-Antoine, Paris, France, ³Inserm, Boulogne Billancourt, France, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁶Lariboisiere Hospital, Paris, France, ⁷Sorbonne Universit - hopital Saint-Antoine, Paris, France, ⁸INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France
Background/Purpose: Hand osteoarthritis (OA) is an heterogenous disease in terms of risk factors, localization and severity. This heterogeneity also applies to the clinical presentation and…
Abstract Number: 0479 • ACR Convergence 2021
A Novel Semi-automated Classifier of Radiographic Hip Osteoarthritis on DXA Scans Is Strongly Predictive of Pain, Clinical Diagnosis and Joint Replacement: Findings from 40,000 Participants in UK Biobank
Benjamin Faber¹, Raja Ebsim², Fiona Saunders³, Monika Frysz¹, Claudia Lindner², Jennifer Gregory³, Richard Aspden³, Nicholas Harvey⁴, George Davey Smith¹, Timothy Cootes² and Jon Tobias¹, ¹University of Bristol, Bristol, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University of Aberdeen, Aberdeen, United Kingdom, ⁴University of Southampton, Southampton, United Kingdom
Background/Purpose: Radiographic hip osteoarthritis (rHOA) is traditionally defined on hip or pelvic radiographs, using subjective methods such as Kellgren-Lawrence scoring. Associations between subjective rHOA measures…
Abstract Number: 0480 • ACR Convergence 2021
Signs of Regression to the Mean in Observational Data from a Nation-Wide Exercise and Education Intervention for Osteoarthritis
Martin Englund¹, Dorte Grønne², Ewa Roos², Søren Skou² and Aleksandra Turkiewicz¹, ¹Lund University, Lund, Sweden, ²University of Southern Denmark, Odense, Denmark
Background/Purpose: Patients who enroll in interventions are likely to do so when they experience a flare-up in symptoms. This may create issues in interpretation of…
Abstract Number: 0481 • ACR Convergence 2021
The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study
Arani Vivekanantham¹, David Selby², Mark Lunt², Terence O’Neill² and Will Dixon², ¹University of Oxford, Oxford, United Kingdom, ²University of Manchester, Manchester, United Kingdom
Background/Purpose: Pain is a cardinal symptom in people with knee osteoarthritis (OA). However, pain in knee OA is often infrequently measured both in clinical practice…
Abstract Number: 0482 • ACR Convergence 2021
Metformin Use Reduces the Risk of Developing Osteoarthritis: A Propensity Score Matching Study
Khushboo Sheth¹, Di Lu², Rong Lu², William Robinson³ and Matthew Baker⁴, ¹Stanford University/VA Palo Alto, Atherton, CA, ²Stanford University, Stanford, ³Stanford University, Palo Alto, CA, ⁴Stanford University, Menlo Park, CA
Background/Purpose: Preclinical and observational data suggest a protective effect of metformin against developing osteoarthritis (OA).1,2 In this retrospective cohort study, we evaluated the time to…
Abstract Number: 0483 • ACR Convergence 2021
Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Tuhina Neogi¹, Andrea Dell'isola², Martin Englund² and Aleksandra Turkiewicz², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Oral NSAIDs are recommended for OA management. However, many patients with OA have contraindications to NSAIDs or have comorbidities that warrant precaution. Because few…
Abstract Number: 0484 • ACR Convergence 2021
RheumMadness: Creating an Online Community of Inquiry
David Leverenz¹, Akrithi Udupa², Didem Saygin³, Guy Katz⁴, Christopher Witt², Lisa Criscione-Schreiber⁵ and Matthew Sparks⁵, ¹Duke University, Durham, NC, ²Duke University Hospital, Durham, NC, ³University of Chicago, Chicago, IL, ⁴Massachusetts General Hospital, Boston, MA, ⁵Duke University School of Medicine, Durham, NC
Background/Purpose: RheumMadness is an online collaborative learning experience in which rheumatology concepts compete as teams in a tournament. The Community of Inquiry (CoI) framework describes…
Abstract Number: 0485 • ACR Convergence 2021
The Impact of COVID-19 on Rheumatology Trainee Health and Wellbeing: Results from the COVID-19 Global Rheumatology Alliance Trainee Survey
Kristen Young¹, Su-Ann Yeoh², Michael Putman³, Sebastian Sattui⁴, Richard Conway⁵, Elizabeth Graef⁶, Adam Killian⁷, Maximilian Konig⁸, Jeffrey Sparks⁹, Manuel Ugarte-Gil¹⁰, Laura Upton¹¹, Francis Berenbaum¹², Suleman Bhana¹³, Jonathan Hausmann¹⁴, Pedro Machado¹⁵, Philip Robinson¹⁶, Emily Sirotich¹⁷, Paul Sufka¹⁸, Jinoos Yazdany¹⁹, Jean Liew²⁰, Rebecca Grainger²¹, Zachary Wallace²² and Aruni Jayatilleke²³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University College London, London, United Kingdom, ³Medical College of Wisconsin, Brookfield, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵St. James's University Hospital, Dublin, Ireland, ⁶Emerson Hospital, Concord, MA, ⁷George Washington University, Washington, DC, ⁸The Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁰Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ¹¹Georgetown University School of Medicine, Melbourne, FL, ¹²Sorbonne Universit - hopital Saint-Antoine, Paris, France, ¹³Crystal Run Health, Montvale, NJ, ¹⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ¹⁶University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ¹⁷McMaster University, Hamilton, ON, Canada, ¹⁸HealthPartners, Eagan, MN, ¹⁹University of California San Francisco, San Francisco, CA, ²⁰Boston University, Boston, MA, ²¹University of Otago, Wellington, New Zealand, ²²Massachusetts General Hospital, Newton, MA, ²³Temple University, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has disrupted healthcare delivery and education of physicians, including rheumatology trainees. Our objective was to assess the impact of the COVID-19…
Abstract Number: 0486 • ACR Convergence 2021
A Practical Approach to Competency-based Evaluations and Milestone Mapping for Adult Rheumatology Fellowship Programs
Grant hughes¹, Sarah Chung¹, Elizabeth Wahl², Jenna Thomason¹, Bernard Ng³, Ingeborg Sacksen⁴ and Alison Bays¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Healthcare System, Seattle, WA, ³Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA, ⁴University of Washington, Bellingham, WA
Background/Purpose: The American College of Rheumatology has developed 14 Entrustable Professional Activities (EPAs) for Adult Rheumatology that define broad clinical competency goals for fellowship. At…
Abstract Number: 0487 • ACR Convergence 2021
A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors
Rachel Wolfe¹, Fotios Koumpouras², Anisha Dua³, Philip Seo⁴, Simon Helfgott⁵ and Beth Jonas⁶, ¹Wake Forest Baptist Health, Winston-Salem, NC, ²Yale School of Medicine, New Haven, CT, ³Northwestern University, Chicago, IL, ⁴Johns Hopkins University, Baltimore, MD, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Clinical educators taking on the new role as program director (PD) must have the time and resources to learn about all the processes (e.g.,…
Abstract Number: 0488 • ACR Convergence 2021
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Philip Mease¹, Philip S Helliwell², Paula Silwinska-Stanczyk³, Malgorzata Miakisz⁴, Andrew Ostor⁵, Elena Peeva⁶, Michael Vincent⁶, Vanja Sikirica⁷, Randall Winnette⁸, Ruolun Qiu⁶, Gang Li⁷, Gang Feng⁶, Jean Beebe⁶ and David Martin⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³REUMATIKA – Centrum Reumatologii NZOZ, Warsaw, Poland, ⁴Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland, ⁵Monash University, Cabrini Hospital & Emeritus Research, Melbourne, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY
Background/Purpose: Brepocitinib is a small-molecule tyrosine kinase 2/Janus kinase 1 inhibitor that has shown promising results in an oral formulation for plaque psoriasis and alopecia…
Abstract Number: 0489 • ACR Convergence 2021
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Kofi Mensah¹, Rajula Gaur¹, Jamie Connarn¹, Michael Thomas¹, Liangang Liu¹, Stuart Mair², Francisco Ramírez-Valle¹ and Maria Palmisano¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Quotient Sciences, Nottingham, United Kingdom
Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…
Abstract Number: 0490 • ACR Convergence 2021
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Oliver FitzGerald¹, Dafna Gladman², Philip Mease³, Christopher Ritchlin⁴, Josef Smolen⁵, Lu Gao⁶, Sarah Hu⁶, Miroslawa Nowak⁶, Subhashis Banerjee⁶, Ian Catlett⁶ and Xiang Guo⁶, ¹Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Medical University of Vienna, Vienna, Austria, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that has demonstrated efficacy in patients (pts)…
Abstract Number: 0491 • ACR Convergence 2021
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Lianne Gensler¹, Atul Deodhar², Désirée van der Heijde³, Denis Poddubnyy⁴, Alan Kivitz⁵, Maxime Dougados⁶, Natasha de Peyrecave⁷, Marga Oortgiesen⁸, Thomas Vaux⁹, Carmen Fleurinck⁷ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Mia Chandler¹, Leah Santacroce², Karen Costenbader³, Rishi Desai⁴, Seoyoung Kim² and Candace Feldman², ¹Boston Children's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Belmont, MA, ⁴Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].